Metabolic Explorer (METEX.PA)
FR0004177046 - Common Stock
We assign a fundamental rating of 2 out of 10 to METEX. METEX was compared to 63 industry peers in the Chemicals industry. METEX has a bad profitability rating. Also its financial health evaluation is rather negative. METEX is quite expensive at the moment. It does show a decent growth rate.
1. Profitability
1.1 Basic Checks
METEX had negative earnings in the past year.
In the past year METEX has reported a negative cash flow from operations.
METEX had negative earnings in 4 of the past 5 years.
METEX had negative operating cash flow in 4 of the past 5 years.
1.2 Ratios
Looking at the Return On Assets, with a value of -19.08%, METEX is doing worse than 89.06% of the companies in the same industry.
METEX has a worse Return On Equity (-51.84%) than 89.06% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | -19.08% | ||
| ROE | -51.84% | ||
| ROIC | N/A |
ROA(3y)-0.39%
ROA(5y)-4.87%
ROE(3y)-8.69%
ROE(5y)-13.58%
ROIC(3y)N/A
ROIC(5y)N/A
1.3 Margins
The Profit Margin and Operating Margin and Gross Margin are not available for METEX so they could not be analyzed.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| OM | N/A | ||
| PM (TTM) | N/A | ||
| GM | N/A |
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
2. Health
2.1 Basic Checks
METEX does not have a ROIC to compare to the WACC, probably because it is not profitable.
METEX has about the same amout of shares outstanding than it did 1 year ago.
Compared to 5 years ago, METEX has more shares outstanding
Compared to 1 year ago, METEX has a worse debt to assets ratio.
2.2 Solvency
METEX has an Altman-Z score of 0.19. This is a bad value and indicates that METEX is not financially healthy and even has some risk of bankruptcy.
The Altman-Z score of METEX (0.19) is worse than 90.63% of its industry peers.
METEX has a Debt/Equity ratio of 0.92. This is a neutral value indicating METEX is somewhat dependend on debt financing.
The Debt to Equity ratio of METEX (0.92) is worse than 79.69% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0.92 | ||
| Debt/FCF | N/A | ||
| Altman-Z | 0.19 |
ROIC/WACCN/A
WACC5.97%
2.3 Liquidity
METEX has a Current Ratio of 2.19. This indicates that METEX is financially healthy and has no problem in meeting its short term obligations.
The Current ratio of METEX (2.19) is better than 64.06% of its industry peers.
A Quick Ratio of 1.31 indicates that METEX should not have too much problems paying its short term obligations.
Looking at the Quick ratio, with a value of 1.31, METEX is in line with its industry, outperforming 57.81% of the companies in the same industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Current Ratio | 2.19 | ||
| Quick Ratio | 1.31 |
3. Growth
3.1 Past
The earnings per share for METEX have decreased strongly by -137.50% in the last year.
The Revenue for METEX has decreased by -36.59% in the past year. This is quite bad
Measured over the past years, METEX shows a very strong growth in Revenue. The Revenue has been growing by 123.77% on average per year.
EPS 1Y (TTM)-137.5%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%32.65%
Revenue 1Y (TTM)-36.59%
Revenue growth 3Y765.1%
Revenue growth 5Y123.77%
Sales Q2Q%-46.56%
3.2 Future
METEX is expected to show a strong growth in Earnings Per Share. In the coming years, the EPS will grow by 23.69% yearly.
METEX is expected to show a small growth in Revenue. In the coming years, the Revenue will grow by 2.34% yearly.
EPS Next Y1.9%
EPS Next 2Y23.83%
EPS Next 3Y23.69%
EPS Next 5YN/A
Revenue Next Year-44.08%
Revenue Next 2Y-9.58%
Revenue Next 3Y2.34%
Revenue Next 5YN/A
3.3 Evolution
The Revenue growth rate is decreasing: in the next years the growth will be less than in the last years.
4. Valuation
4.1 Price/Earnings Ratio
METEX reported negative earnings for the last year, which makes the Price/Earnings Ratio negative.
Besides the negative Price/Earnings Ratio, also the Forward Price/Earnings Ratio is negative for METEX. No positive earnings are expected for the next year.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | N/A | ||
| Fwd PE | N/A |
4.2 Price Multiples
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| P/FCF | N/A | ||
| EV/EBITDA | N/A |
4.3 Compensation for Growth
A more expensive valuation may be justified as METEX's earnings are expected to grow with 23.69% in the coming years.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y23.83%
EPS Next 3Y23.69%
5. Dividend
5.1 Amount
METEX does not give a dividend.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
Metabolic Explorer
EPA:METEX (5/6/2024, 7:00:00 PM)
0.1214
+0 (+1.17%)
Chartmill FA Rating
GICS SectorMaterials
GICS IndustryGroupMaterials
GICS IndustryChemicals
Earnings (Last)
Earnings (Next)
Inst OwnersN/A
Inst Owner ChangeN/A
Ins OwnersN/A
Ins Owner ChangeN/A
Market Cap6.16M
Analysts34.29
Price Target0.2 (64.74%)
Short Float %N/A
Short RatioN/A
Dividend
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)N/A
Avg EPS beat(2)N/A
Min EPS beat(2)N/A
Max EPS beat(2)N/A
EPS beat(4)N/A
Avg EPS beat(4)N/A
Min EPS beat(4)N/A
Max EPS beat(4)N/A
EPS beat(8)N/A
Avg EPS beat(8)N/A
EPS beat(12)N/A
Avg EPS beat(12)N/A
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)N/A
Avg Revenue beat(2)N/A
Min Revenue beat(2)N/A
Max Revenue beat(2)N/A
Revenue beat(4)N/A
Avg Revenue beat(4)N/A
Min Revenue beat(4)N/A
Max Revenue beat(4)N/A
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)0%
PT rev (3m)-55.56%
EPS NQ rev (1m)N/A
EPS NQ rev (3m)N/A
EPS NY rev (1m)0%
EPS NY rev (3m)12.21%
Revenue NQ rev (1m)N/A
Revenue NQ rev (3m)N/A
Revenue NY rev (1m)0%
Revenue NY rev (3m)-1.23%
Valuation
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | N/A | ||
| Fwd PE | N/A | ||
| P/S | 0.04 | ||
| P/FCF | N/A | ||
| P/OCF | N/A | ||
| P/B | 0.06 | ||
| P/tB | 0.08 | ||
| EV/EBITDA | N/A |
EPS(TTM)-0.95
EYN/A
EPS(NY)-0.4
Fwd EYN/A
FCF(TTM)-1.07
FCFYN/A
OCF(TTM)-0.75
OCFYN/A
SpS3.28
BVpS1.88
TBVpS1.59
PEG (NY)N/A
PEG (5Y)N/A
Profitability
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | -19.08% | ||
| ROE | -51.84% | ||
| ROCE | N/A | ||
| ROIC | N/A | ||
| ROICexc | N/A | ||
| ROICexgc | N/A | ||
| OM | N/A | ||
| PM (TTM) | N/A | ||
| GM | N/A | ||
| FCFM | N/A |
ROA(3y)-0.39%
ROA(5y)-4.87%
ROE(3y)-8.69%
ROE(5y)-13.58%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexcg growth 3YN/A
ROICexcg growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-Score2
Asset Turnover0.64
Health
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0.92 | ||
| Debt/FCF | N/A | ||
| Debt/EBITDA | N/A | ||
| Cap/Depr | 254.32% | ||
| Cap/Sales | 9.74% | ||
| Interest Coverage | N/A | ||
| Cash Conversion | N/A | ||
| Profit Quality | N/A | ||
| Current Ratio | 2.19 | ||
| Quick Ratio | 1.31 | ||
| Altman-Z | 0.19 |
F-Score2
WACC5.97%
ROIC/WACCN/A
Cap/Depr(3y)1451.31%
Cap/Depr(5y)1065.24%
Cap/Sales(3y)15548.8%
Cap/Sales(5y)10277%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)-137.5%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%32.65%
EPS Next Y1.9%
EPS Next 2Y23.83%
EPS Next 3Y23.69%
EPS Next 5YN/A
Revenue 1Y (TTM)-36.59%
Revenue growth 3Y765.1%
Revenue growth 5Y123.77%
Sales Q2Q%-46.56%
Revenue Next Year-44.08%
Revenue Next 2Y-9.58%
Revenue Next 3Y2.34%
Revenue Next 5YN/A
EBIT growth 1Y-165.5%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year-30.98%
EBIT Next 3Y37.59%
EBIT Next 5YN/A
FCF growth 1Y-192.66%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y-3320.34%
OCF growth 3YN/A
OCF growth 5YN/A